Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

Tiia Koho; Minni R L Koivunen; Sami Oikarinen; Laura Kummola; Selina Mäkinen; Anssi J Mähönen; Amirbabak Sioofy-Khojine; Varpu Marjomäki; Artur Kazmertsuk; Ilkka Junttila; Markku S Kulomaa; Heikki Hyöty; Vesa P Hytönen; Olli H Laitinen

doi:10.1016/j.antiviral.2014.01.013

Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

Antiviral Res. 2014 Apr:104:93-101. doi: 10.1016/j.antiviral.2014.01.013. Epub 2014 Jan 28.

Affiliations

¹ BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland.
² Vactech Ltd, Biokatu 8, FI-33520 Tampere, Finland.
³ Department of Virology, School of Medicine, Biokatu 10, FI-33014 University of Tampere, Finland.
⁴ School of Medicine, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
⁵ Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, P.O. Box 35, FI-40014 University of Jyväskylä, Finland.
⁶ Department of Virology, School of Medicine, Biokatu 10, FI-33014 University of Tampere, Finland; School of Medicine, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
⁷ BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
⁸ Vactech Ltd, Biokatu 8, FI-33520 Tampere, Finland; The Center for Infectious Medicine, Department of Medicine HS, Karolinska Institutet, Karolinska University Hospital Huddinge F59, SE-141 86 Stockholm, Sweden. Electronic address: [email protected].

PMID: 24485896
DOI: 10.1016/j.antiviral.2014.01.013

Abstract

Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and production on an industrial scale. The produced VLPs were characterized using a number of biophysical methods and exhibited excellent quality and high purity. Immunization of mice with VLPs elicited a strong immune response, demonstrating the excellent vaccine potential of these VLPs.

Keywords: CVB3; Ion exchange chromatography; VLP.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Viral / immunology
Antibody Specificity
Baculoviridae / genetics
Chromatography, Ion Exchange
Coxsackievirus Infections / immunology*
Coxsackievirus Infections / prevention & control
Disease Models, Animal
Enterovirus B, Human / immunology*
Female
Gene Order
Genetic Vectors / genetics
Immunity, Cellular
Immunization
Mice
Vaccines, Virus-Like Particle / immunology*
Vaccines, Virus-Like Particle / isolation & purification
Vaccines, Virus-Like Particle / ultrastructure

Substances

Antibodies, Viral
Vaccines, Virus-Like Particle